The move comes amid HHS Secretary Robert F. Kennedy Jr.’s decision to force out the top official responsible for reviewing ...
Shares of Novavax Inc. NVAX slid 6.35% to $5.60 Thursday, on what proved to be an all-around dismal trading session for the ...
Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...
Novavax's COVID-19 vaccine received FDA Emergency Use Authorization, but full approval faces delays as regulators request more data beyond the April 1 deadline.
The FDA was scheduled to release its decision on Novavax’s updated, protein-based COVID-19 vaccine on April 1.
President Trump yesterday announced a baseline tariff of 10% on all imported products and higher rates on certain countries ...
Novavax (NasdaqGS:NVAX) recently experienced a significant decline of 21% over the past week, coinciding with leadership changes, including the retirement of longtime Chairman James Young and the ...
The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...
The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback